- Home
- JSPR vs EPIX Comparison
JSPR vs EPIX Comparison
Compare JSPR & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- EPIX
- Stock Information
- Founded
- JSPR 2018
- EPIX 2009
- Country
- JSPR United States
- EPIX Canada
- Employees
- JSPR N/A
- EPIX N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- EPIX Health Care
- Exchange
- JSPR Nasdaq
- EPIX Nasdaq
- Market Cap
- JSPR 85.8M
- EPIX 65.3M
- IPO Year
- JSPR N/A
- EPIX N/A
- Fundamental
- Price
- JSPR $4.43
- EPIX $1.71
- Analyst Decision
- JSPR Strong Buy
- EPIX Hold
- Analyst Count
- JSPR 10
- EPIX 3
- Target Price
- JSPR $62.50
- EPIX $2.00
- AVG Volume (30 Days)
- JSPR 155.4K
- EPIX 276.9K
- Earning Date
- JSPR 05-20-2025
- EPIX 05-08-2025
- Dividend Yield
- JSPR N/A
- EPIX N/A
- EPS Growth
- JSPR N/A
- EPIX N/A
- EPS
- JSPR N/A
- EPIX N/A
- Revenue
- JSPR N/A
- EPIX N/A
- Revenue This Year
- JSPR N/A
- EPIX N/A
- Revenue Next Year
- JSPR N/A
- EPIX N/A
- P/E Ratio
- JSPR N/A
- EPIX N/A
- Revenue Growth
- JSPR N/A
- EPIX N/A
- 52 Week Low
- JSPR $3.13
- EPIX $1.40
- 52 Week High
- JSPR $26.84
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- JSPR 44.42
- EPIX 51.16
- Support Level
- JSPR $4.27
- EPIX $1.74
- Resistance Level
- JSPR $5.67
- EPIX $1.85
- Average True Range (ATR)
- JSPR 0.44
- EPIX 0.08
- MACD
- JSPR 0.01
- EPIX -0.01
- Stochastic Oscillator
- JSPR 28.32
- EPIX 13.33
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.